Search Within

Matthew David Hellmann

  1. "2015"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (7)
Groups
  1. Department of Medicine (20)
  2. Solid Tumor Oncology Division (20)
  3. Thoracic Oncology (20)
  4. GSK Faculty (5)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)
  6. Melanoma and Immunotherapeutics Service (3)

More Groups

People
  1. Naiyer Rizvi (6)
  2. Jamie Chaft (3)
  3. Jedd Wolchok (3)
  4. Alexander Drilon (2)
  5. Alexandra Snyder Charen (2)
  6. Camelia Sima (2)

More People

Years
  1. 2015 (20)
Publications
  1. Journal of Thoracic Oncology (6)
  2. European Journal of Cancer (4)
  3. Journal of Clinical Oncology (3)
  4. Annals of Oncology (1)
  5. Cancer (1)
  6. Clinical Lung Cancer (1)

More Publications

Publishers
  1. Elsevier Inc. (11)
  2. American Society of Clinical Oncology (3)
  3. American Association for the Advancement of Science (1)
  4. Biomed Central Ltd (1)
  5. Landes Bioscience (1)
  6. Massachusetts Medical Society (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An open label randomized phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
    Meeting Abstract

    Hellmann, M.; Ramalingam, S.; Reck, M.; O'Byrne, K.; Paz-Ares, L.; Harbison, C. T.; Bhagavatheeswaran, P.; Nathan, F.; Brahmer, J.
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • Pembrolizumab 2 mg/kg Q3W for previously treated, PD-L1-positive advanced NSCLC
    Meeting Abstract

    Fløtten, Ø.; Garon, E. B.; Arkenau, H. T.; Hui, R.; Gandhi, L.; Felip, E.; Lena, H.; Cappuzzo, F.; Horn, L.; Gubens, M.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy of pembrolizumab in key subgroups of patients with advanced NSCLC
    Meeting Abstract

    Hellmann, M. D.; Garon, E. B.; Gandhi, L.; Hui, R.; Zhang, J.; Rangwala, R.; Lubiniecki, G.; Rizvi, N. A.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Pembrolizumab for NSCLC: Immune-mediated adverse events and corticosteroid use
    Meeting Abstract

    Leighl, N.; Gandhi, L.; Hellmann, M. D.; Horn, L.; Ahn, M. J.; Garon, E. B.; Hui, R.; Ramalingam, S. S.; Zhang, J.; Lubiniecki, G.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Rizvi, N. A.; Gettinger, S. N.; Goldman, J. W.; Hellmann, M. D.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Brahmer, J. R.; Shen, Y.; Harbison, C.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Spatiotemporal effects on programmed death ligand 1 (PD-L1) expression and immunophenotype of non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kowanetz, M.; Koeppen, H.; Boe, M.; Chaft, J. E.; Rudin, C. M.; Zou, W.; Nickles, D.; Desai, R.; Nakamura, R.; Sandler, A.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001
    Meeting Abstract

    Ahn, M. J.; Gandhi, L.; Hamid, O.; Hellmann, M. D.; Garon, E. B.; Ramalingam, S. S.; Lubiniecki, G. M.; Zhang, J.; Piperdi, B.; Hui, R.
    Annals of Oncology (2015)

    Fulltext@MSK | Save
  • Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas
    Journal Article

    Eng, J.; Woo, K. M.; Sima, C. S.; Plodkowski, A.; Hellmann, M. D.; Chaft, J. E.; Kris, M. G.; Arcila, M. E.; Ladanyi, M.; Drilon, A.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of pembrolizumab (pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001
    Meeting Abstract

    Soria, J. C.; Flotten, O.; Horn, L.; Felip, E.; Gandhi, L.; Hui, R.; Hellmann, M.; Leighl, N.; Zhang, J.; Kondic, A.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Hellmann, M. D.; Rizvi, N.; Gettinger, S. N.; Goldman, J.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Brahmer, J.; Shen, Y.; Harbison, C. T.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save